Rolofylline flunks Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Merck will not file an application for regulatory approval of rolofylline in 2009 as initially planned because a pivotal study of the adenosine A1 receptor antagonist failed to meet its primary or secondary efficacy endpoints. Merck had thought the drug had potential to be the first major acute heart failure therapy that preserves renal function and improves outcomes after an earlier pilot study showed an overall trend toward efficacy (1Start-Up, September 2007). Merck said June 5 that rolofylline did no better than placebo in the 2,033-patient PROTECT study in improving symptoms of acute heart failure, nor did it reduce the risk of death or cardiovascular or renal re-hospitalization versus placebo by 60 days after treatment. Merck plans to present more explicit results at a meeting later this year. Rolofylline was not expected to be a big seller, but the loss of yet another Phase III compound, particularly a cardiovascular drug, is a blow for Merck - and drives home the rationale for its merger with Schering-Plough (2"The Pink Sheet," March 16, 2009, p. 18)
You may also be interested in...
Bulking up the pipeline is a frequent motive for a pharmaceutical merger - but somewhat unusual for Merck, a company that has long prided itself on the strength of its R&D activity
Domain partner Eckard Weber has become a master of the one-two punch in venture investing. The process (now in its third iteration following Merck's $350 million acquisition of NovaCardia): find a drug no one cares about; create a low-infrastructure company around it; find a second drug; sell off the lead drug through an acquisition; develop the second drug a bit more with the same management; then sell that one too. The first deal at a minimum pays back the investors; the second deal juices the returns. It's a model many VCs want to follow.
FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions
Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.